Fluicell AB (publ) (FLUI.ST) Research

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.

Market snapshot

Symbol
FLUI.ST
Price
$34.70
Day change
+9.46%
Market cap
$47.7M
P/E ratio
-20.33x
52-week range
7.45-67.2
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • 2cureX AB (publ) (2CUREX.ST)
  • Aptahem AB (publ) (APTA.ST)
  • Chordate Medical Holding AB (publ) (CMH.ST)
  • Guard Therapeutics International AB (publ) (GUARD.ST)
  • LIDDS AB (publ) (LIDDS.ST)
  • ODI Pharma AB (ODI.ST)
  • Prostatype Genomics AB (publ) (PROGEN.ST)
  • Quia Pharma AB (publ) (QUIA.ST)

Open Fluicell AB (publ) (FLUI.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.